MADISON HEIGHTS, Mich.,
Oct. 2, 2018 /PRNewswire/
-- InfuSystem Holdings, Inc. (NYSE American: INFU)
("InfuSystem" or the "Company"), a leading national provider of
infusion pumps and related services for the healthcare industry in
the United States and Canada, today announced it will feature its
InfuBLOCK Post-Op Pain Management program at Outpatient Surgery
Magazine's OR Excellence Conference, taking place on October 3 – 5 at the Harbor Beach Marriott Resort
and Spa in Fort Lauderdale,
Florida.
Neill Saunders, InfuBLOCK's
Division Director said, "InfuBLOCK for both the outpatient and
inpatient settings, gives continuous peripheral nerve block
programs a convenient and cost-saving way to do more blocks for
more patients, reducing the reliance on opioid pain medication for
post-surgical recovery. And the patients love it. Our
satisfaction scores are consistently higher than 9 out of 10, which
our customers love. InfuBLOCK offers superior accuracy in
delivering the correct amount of medication in the infusion process
compared to balloon-type infusion devices, helps manage our
patient's pain better. Patients on the program are contacted
daily by our InfuBLOCK team to monitor progress, pain levels, and
satisfaction. InfuBLOCK's ultra-high patient satisfaction
scores show InfuBLOCK's ability to effectively manage pain while
avoiding the deleterious effects associated with taking opioid
medications."
According to the National Institutes of Health, "Taking opioids
over a long period of time produces dependence, such that when
people stop taking the drug, they have physical and psychological
symptoms of withdrawal. Dependence is not the same thing as
addiction; although everyone who takes opioids for an extended
period will become dependent.
"Misuse of prescription opioids and heroin affects more than 2
million Americans and an estimated 15 million people worldwide each
year. The prevalence of opioid misuse and addiction is rapidly
increasing. In 2016, more than 20,000 deaths in the United States were caused by an overdose
of prescription opioids, and another 13,000 deaths resulted from
heroin overdose. Drug overdoses are now the leading cause of death
in U.S. adults under age 50, and opioids account for more than half
of all drug overdose deaths."
Mr. Saunders continued, "InfuBLOCK is an effective and safe
protocol for managing post-operative pain. Patients recover in the
comfort of their own home with a non-opioid, consistent method for
pain management along with our entire team to support them as they
recover. Helping patients manage post-op pain as they heal,
while minimizing their reliance on opioid pain medications, is our
cause and is more important today than ever. While opioid
medications have a place in the overall treatment of pain,
InfuBLOCK can be a superior alternative to going home with opioid
pain medications alone.
"Additionally, facilities that offer the InfuBLOCK program will
experience significant cost savings compared to balloon-type
elastomeric pumps currently in use. We look forward to showcasing
InfuBLOCK at Outpatient Surgery Magazine's OR Excellence Conference
on October 3 – 5, 2018 in
Fort Lauderdale, Florida."
About InfuSystem Holdings, Inc.
InfuSystem Holdings,
Inc. is a leading provider of infusion pumps and related services
to hospitals, oncology practices and other alternate site
healthcare providers. Headquartered in Madison Heights, Michigan, the Company
delivers local, field-based customer support and also operates
Centers of Excellence in Michigan,
Kansas, California, Georgia and Ontario,
Canada. The Company's stock is traded on the NYSE American
under the symbol INFU.
Forward-Looking Statements
Statements made in
this press release that are not historical facts are considered to
be forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended (the "Securities Act") and
Section 21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"). The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "should," "plan," "expect,"
"strategy," "future," "likely," variations of such words, and other
similar expressions, as they relate to the Company, are intended to
identify forward-looking statements. However, the absence of these
words or similar expressions does not mean that a statement is not
forward-looking. Forward-looking statements include statements
relating to future actions, business plans, objectives and
prospects, future operating or financial performance, including the
preliminary financial results contained in this press release. In
connection with the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, the Company is
identifying certain factors that could cause actual results to
differ, perhaps materially, from those indicated by these
forward-looking statements. Those factors, risks and uncertainties
include, but are not limited to, the potential changes in overall
healthcare reimbursement, including Centers for Medicaid and
Medicare Services ("CMS") competitive bidding and fee schedule
reductions, sequestration, concentration of customers, increased
focus on early detection of cancer, competitive treatments,
dependency on Medicare Supplier Number, availability of
chemotherapy drugs, global financial conditions, changes and
enforcement of state and federal laws, natural forces, competition,
dependency on suppliers, risks in acquisitions & joint
ventures, U.S. Healthcare Reform, relationships with healthcare
professionals and organizations, technological changes related to
infusion therapy, the Company's ability to implement information
technology improvements and to respond to technological changes,
dependency on websites and intellectual property, the ability of
the Company to successfully integrate acquired businesses,
dependency on key personnel, dependency on banking relations and
the ability to comply with Credit Facility covenants, and other
risks associated with its common stock, as well as any litigation
to which the Company may be involved in from time to time; and
other risk factors as discussed in the Company's annual report on
Form 10-K for the year ended December 31,
2017 and in other filings made by the Company from time to
time with the Securities and Exchange Commission, including its
quarterly reports on Form 10-Q. Our annual report on Form 10-K is
available on the SEC's EDGAR website at www.sec.gov, and a copy may
also be obtained by contacting the Company. All forward-looking
statements made in this press release speak only as of the date
hereof. We do not intend, and do not undertake any obligation, to
update any forward-looking statements to reflect future events or
circumstances after the date of such statements, except as required
by law.
Additional information about InfuSystem Holdings, Inc. is
available at www.infusystem.com.
CONTACT:
|
Joe Dorame, Joe Diaz
& Robert Blum
|
|
Lytham Partners,
LLC
|
|
602-889-9700
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/infusystem-holdings-to-feature-infublock--its-highly-effective-alternative-to-opioid-pain-management---at-outpatient-surgery-magazines-or-excellence-conference-300722497.html
SOURCE InfuSystem Holdings, Inc.